Patrick F. Fogarty, MD
Patrick F. Fogarty, MD, is Assistant Professor of Medicine at the Perelman School of Medicine at the University of Pennsylvania in Philadelphia, Pennsylvania and Director of the Penn Comprehensive Hemophilia and Thrombosis Program, Hospital of the University of Pennsylvania.
After earning his medical degree from Jefferson Medical College, Philadelphia, Pennsylvania, Dr. Fogarty completed his residency in Internal Medicine at Georgetown University Medical Center in Washington, DC. He then went on to complete a fellowship in Hematology/Oncology and a clinical research fellowship in Hemostasis and Thrombosis at the National Heart, Lung, and Blood Institute of the National Institutes of Health, in Bethesda, Maryland. He then was appointed Director of the Adult Hemophilia Program and Co-Director of the UCSF Comprehensive Hemophilia Treatment Center, University of California, San Francisco, where he was an Associate Professor of Clinical Medicine in the Division of Hematology/Oncology.
Dr. Fogarty is board-certified in hematology and medical oncology. He is a member of the Hemostasis and Thrombosis Research Society, the American Society of Hematology, the International Society on Haemostasis and Thrombosis, the National Hemophilia Foundation, and the World Federation of Haemophilia.
He maintains an active program in clinical research in hemostasis and thrombosis; recent investigations have included validation of bleeding scores and epidemiologic assessments of co-morbidities affecting inherited and acquired disorders of hemostasis. He is a panel member and author of the National Comprehensive Cancer Network’s Guideline for Supportive Care, Venous Thromboembolic Disease. He is a member of the Steering Committee for U.S. pilot studies in hemophilia. Dr. Fogarty serves as a reviewer for numerous peer-reviewed journals. He is frequently invited to speak at national and international meetings on disorders of hemostasis and thrombosis, and has contributed to/edited multiple reference volumes on bleeding and clotting conditions.
Therapeutic Advances in the Management of Hemophilia